Retatrutide vs tirzepatide comparison

Phase 3 data shows retatrutide produces approximately 24.9% mean weight loss vs 22.5% with tirzepatide — an absolute difference of approximately 2-3 percentage points. At higher body weights, this percentage difference translates to more kg lost. Additionally, retatrutide shows no weight loss plateau at 96 weeks, while tirzepatide shows stabilization around 72 weeks — suggesting retatrutide's superiority may increase with longer treatment duration.

Tirzepatide activates GIP and GLP-1 receptors. Retatrutide activates GIP, GLP-1, and glucagon receptors. The glucagon receptor addition drives hepatic fat oxidation, increases ketone body production, and prevents the adaptive thermogenesis (reduced energy expenditure) that causes weight loss to plateau with GLP-1-based therapies. The glucagon component is also responsible for retatrutide's superior NAFLD outcomes — 86% liver fat clearance vs approximately 60% with GLP-1 monotherapy.

Both compounds have similar GI adverse event rates (approximately 65-73%). Retatrutide has an additional unique side effect: paresthesia (tingling/numbness) in 12.5% of participants, attributed to glucagon receptor activity. Tirzepatide does not produce paresthesia. Retatrutide also shows greater heart rate increase (4.8 bpm vs 2-3 bpm with tirzepatide). For researchers prioritizing tolerability, tirzepatide has the better-established side effect profile and FDA approval.

Based on Phase 3 completion timelines and Eli Lilly's regulatory filing plans, retatrutide FDA submission is anticipated in late 2026 with a potential approval decision in late 2027. This would make retatrutide available approximately 2-3 years after tirzepatide's obesity approval (Zepbound, 2023). EMA review is proceeding in parallel.

Combining two incretin-based therapies targeting overlapping receptors (both activate GIP and GLP-1 receptors) is not supported by clinical data and would not be expected to provide additive efficacy — the receptors would be saturated by either agent alone at therapeutic doses. Using both simultaneously would increase adverse event risk without mechanistic justification. Choose one compound as the primary GLP-1/GIP agonist for a given protocol.